# Vittoria Biotherapeutics

Source: https://onco.cc/companies/vittoria-biotherapeutics/  
OnCo record `vittoria-biotherapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Vittoria Biotherapeutics makes CAR-T cell therapy, a patient's own immune cells engineered to attack cancer, for T-cell lymphoma, a cancer of the same kind of cell that CAR-T is made from. Its first product, VIPER-101, is in an early trial.

## Summary

Vittoria Biotherapeutics, Inc., at 3675 Market Street, Philadelphia, is a clinical-stage company whose Senza5 platform modulates CD5 signalling and uses a five-day manufacturing process for autologous CAR-T cells. Its lead product VIPER-101 (Senza5 CART5) is a gene-edited, autologous, dual-population CD5-directed CAR-T in which CD5 is deleted from the engineered cells; an open-label phase 1 study with the University of Pennsylvania in T-cell non-Hodgkin lymphoma (NCT06420089) dosed its first patient in December 2024. Further programmes VIPER-102 and VIPER-103 are listed. The chief executive and co-founder is Nicholas Siciliano. Its first registered cancer trial, NCT06420089, was posted on ClinicalTrials.gov in May 2024.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: viTToria Biotherapeutics
- HQ: Philadelphia, PA
- Type: cell-therapy
- Website: https://www.vittoriabio.com/

## Notes

- Read on 29 October 2026: vittoriabio.com home, about and pipeline pages. Founding year and financing not stated on the pages read. No CD5 target record exists in OnCo.
- Trial facts from the ClinicalTrials.gov record NCT06420089, read on 29 October 2026.

## Sources

- Official website: https://www.vittoriabio.com/
- Pipeline: https://vittoriabio.com/pipeline/
- ClinicalTrials.gov: phase 1 trial of Senza5 CART5 (VIPER-101) in T-cell lymphoma (NCT06420089): https://clinicaltrials.gov/study/NCT06420089

## Connected records

- cancers: [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)

---
JSON: https://onco.cc/api/v1/entities/vittoria-biotherapeutics.json